Expected survival , 6 weeks;. *ANC≥ 1×10^6/L3PLT ≥ 1×10^8/L; ... Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat ... Experimental: Sarcoma-specific CAR-T cells Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, ... Biological: Sarcoma-specific CAR-T cells 1 infusion, for 1x10^6~1x10^7 cells/kg via IV ...
Progression-free survival (PFS) is defined as the time from first STP938 dose to the date of disease progression or death, ... A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas. The safety and scientific ... Lymphoma, B-Cell Lymphoma, T-Cell Drug: STP938 Phase 1 Phase 2 ... Lymphoma, T-Cell. Lymphoma, B-Cell. Neoplasms by Histologic ... Genetic and Rare Diseases Information Center resources: Lymphosarcoma B-cell Lymphoma Peripheral T-cell Lymphoma ...
Since tyrosine kinase inhibitors (TKIs) have become available, the median survival of GIST patients increased from 9 months to ... and may cause resistance due to drug underexposure and thereby proliferation of the least sensitive tumor cells. This offers ...
Co-morbid conditions that may limit survival to less than 12 months ... sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; postpartum angiopathy; suspected ... or leading to transfusion of two units or more of whole blood or red cells ...
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of ... Overall Survival (OS) in Participants With PD-L1 CPS ≥1 [ Time Frame: Up to approximately 46 months ]. OS was defined as the ... Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by ... Programmed Cell Death-1 (PD1, PD-1). Programmed Death-Ligand 1 (PDL1, PD-L1). ...
Squamous Cell Carcinoma of Head and Neck. Kidney Neoplasms. Cystadenocarcinoma, Serous. Carcinoma, Squamous Cell. Carcinoma. ... Overall survival [ Time Frame: For the duration of the study (12 weeks after the final dose of study treatment) ]. The overall ... Triple Negative Breast Cancer Renal Cell Cancer High Grade Ovarian Serous Adenocarcinoma Squamous Cell Carcinoma of the Head ... Immune cell profiling in tumour samples [ Time Frame: For the duration of the study (12 weeks after the final dose of study ...
Sugawara K, Zakany N, Tiede S, Purba T, Harries M, Tsuruta D, Biro T, Paus R. Human epithelial stem cell survival within their ...
Overall survival (OS) [ Time Frame: Up to 7 years ]. Overall survival will be calculated as the time from start of treatment ... Platelet count , 75,000/μL for subjects in whom , 50% of bone marrow nucleated cells are plasma cells; or a platelet count , ... Progression-free survival (PFS) [ Time Frame: Up to 7 years ]. Progression-free survival will be calculated as the time from ... This trial will assess, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), Duration of ...
Progression-free survival (PFS) at 12 and 24 months [ Time Frame: 24 months approximately ]. *Event-free survival (EFS) at 12 ... Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Neoplasms by Histologic Type. Neoplasms. Lymphoproliferative Disorders. ... Genetic and Rare Diseases Information Center resources: Lymphosarcoma B-cell Lymphoma Diffuse Large B-Cell Lymphoma ... Diffuse Large B-cell Lymphoma Drug: Tafasitamab Drug: Tafasitamab plus lenalidomide Phase 1 ...
... work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by ... Overall survival (OS) [ Time Frame: From study entry to death due to any cause, assessed up to 5 years after study enrollment ] ... Event-free survival (EFS) [ Time Frame: From study entry to the earliest of relapse or disease progression, second malignant ... Hemoglobin ,= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (performed within 7 days prior to enrollment) ...
Progressioin free survival (PFS) [ Time Frame: Up to 3 years ]. Progression free survival (PFS) is defined as the time from ... Lymphoma, B-Cell, Marginal Zone. Lymphoma. Neoplasms by Histologic Type. Neoplasms. Lymphoproliferative Disorders. Lymphatic ... Overall survival (OS) [ Time Frame: Up to 3 years ]. Overall survival is defined as the period from the induction registration ... Prior organ or hematopoietic stem cell transplant. *Major surgery within 6 weeks of screening, except for diagnostic test or ...
Renal Cell Carcinoma Esophageal Cancer Clear Cell Renal Cell Carcinoma Bile Duct Cancer Neuroepithelioma Glioma ... Overall survival is defined as the date from start of the study treatment to the date of death due to any cause. ... Neoplasms, Germ Cell and Embryonal. Neoplasms, Nerve Tissue. Carcinoma, Squamous Cell. Adenocarcinoma. Astrocytoma. Glioma. ... Mesothelioma Glioblastoma Renal Cell Carcinoma Non Small Cell Lung Cancer Melanoma Pancreatic Ductal Adenocarcinoma Gastric ...
All Cohorts: Overall Survival (OS) [ Time Frame: Baseline up to approximately 6 years ]. *All Cohorts: Percentage of ... Non-Small Cell Lung Cancer Drug: Alectinib Drug: Atezolizumab Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Drug: ... Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. ... A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell ...